Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Nelfinavir and Lamivudine pharmacokinetics during the first two weeks of life.

Mirochnick M, Nielsen-Saines K, Pilotto JH, Pinto J, Veloso VG, Rossi S, Moye J, Bryson Y, Mofenson L, Camarca M, Watts DH; NICHD HPTN 040/PACTG 1043 PROTOCOL Team.

Pediatr Infect Dis J. 2011 Sep;30(9):769-72. doi: 10.1097/INF.0b013e3182242950.

2.

Safety and pharmacokinetics of nelfinavir coadministered with zidovudine and lamivudine in infants during the first 6 weeks of life.

Mirochnick M, Stek A, Acevedo M, Keller M, Holland D, Capparelli E, Connor J, Huang S, Hughes M, Watts H, Mofenson L, Bryson Y.

J Acquir Immune Defic Syndr. 2005 Jun 1;39(2):189-94.

PMID:
15905735
3.

The pharmacokinetics of nelfinavir in HIV-1-infected children.

van Heeswijk RP, Scherpbier HJ, de Koning LA, Heymans HS, Lange JM, Beijnen JH, Hoetelmans RM.

Ther Drug Monit. 2002 Aug;24(4):487-91.

PMID:
12142631
4.

Pharmacokinetics of nelfinavir in human immunodeficiency virus-infected infants.

Capparelli EV, Sullivan JL, Mofenson L, Smith E, Graham B, Britto P, Becker MI, Holland D, Connor JD, Luzuriaga K; Pediatric ACTG 356 Investigators.

Pediatr Infect Dis J. 2001 Aug;20(8):746-51.

PMID:
11734735
5.

Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353.

Bryson YJ, Mirochnick M, Stek A, Mofenson LM, Connor J, Capparelli E, Watts DH, Huang S, Hughes MD, Kaiser K, Purdue L, Asfaw Y, Keller M, Smith E; PACTG 353 Team.

HIV Clin Trials. 2008 Mar-Apr;9(2):115-25. doi: 10.1310/hct0902-115.

7.

The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection.

Elion R, Kaul S, Knupp C, Adler M, Cross AP, Dunkle LM, Kelleher T.

Clin Ther. 1999 Nov;21(11):1853-63.

PMID:
10890257
8.

Population pharmacokinetics of lamivudine in human immunodeficiency virus-exposed and -infected infants.

Tremoulet AH, Capparelli EV, Patel P, Acosta EP, Luzuriaga K, Bryson Y, Wara D, Zorrilla C, Holland D, Mirochnick M; Pediatric AIDS Clinical Trials Group.

Antimicrob Agents Chemother. 2007 Dec;51(12):4297-302. Epub 2007 Sep 24.

9.

Pharmacokinetics of nelfinavir in children: influencing factors and dose implications.

Bergshoeff AS, Fraaij PL, van Rossum AM, Wolfs TF, Geelen SP, de Groot R, Burger DM.

Antivir Ther. 2003 Jun;8(3):215-22.

PMID:
12924538
10.

Clinical pharmacokinetics of nelfinavir combined with efavirenz and stavudine during rescue treatment of heavily pretreated HIV-infected patients.

Regazzi MB, Villani P, Maserati R, Seminari E, Pan A, LoCaputo F, Gambarana E, Fiocchi C.

J Antimicrob Chemother. 2000 Mar;45(3):343-7.

PMID:
10702554
12.

Persistence of genotypic resistance to nelfinavir among women exposed to prophylactic antiretroviral therapy during pregnancy.

Kakehasi FM, Tupinambás U, Cleto S, Aleixo A, Lin E, Melo VH, Aguiar RA, Pinto JA.

AIDS Res Hum Retroviruses. 2007 Dec;23(12):1515-20.

PMID:
18160009
13.

Preliminary experiences with triple therapy including nelfinavir and two reverse transcriptase inhibitors in previously untreated HIV-infected children.

Funk MB, Linde R, Wintergerst U, Notheis G, Hoffmann F, Schuster T, Kornhuber B, Ahrens P, Kreuz W.

AIDS. 1999 Sep 10;13(13):1653-8.

PMID:
10509566
14.

Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring.

Moodley J, Moodley D, Pillay K, Coovadia H, Saba J, van Leeuwen R, Goodwin C, Harrigan PR, Moore KH, Stone C, Plumb R, Johnson MA.

J Infect Dis. 1998 Nov;178(5):1327-33.

PMID:
9780252
15.

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, Johnson M, Johnson D, Lalonde R, Japour A, Brun S, Sun E; M98-863 Study Team.

N Engl J Med. 2002 Jun 27;346(26):2039-46.

16.

Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study).

Pellegrin I, Breilh D, Montestruc F, Caumont A, Garrigue I, Morlat P, Le Camus C, Saux MC, Fleury HJ, Pellegrin JL.

AIDS. 2002 Jul 5;16(10):1331-40.

PMID:
12131209
17.

The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1.

Moore KH, Barrett JE, Shaw S, Pakes GE, Churchus R, Kapoor A, Lloyd J, Barry MG, Back D.

AIDS. 1999 Nov 12;13(16):2239-50.

PMID:
10563709
18.

Developmental pharmacokinetics of lamivudine in 580 pediatric patients ranging from neonates to adolescents.

Bouazza N, Hirt D, Blanche S, Frange P, Rey E, Tréluyer JM, Urien S.

Antimicrob Agents Chemother. 2011 Jul;55(7):3498-504. doi: 10.1128/AAC.01622-10. Epub 2011 May 16.

19.

Pharmacokinetics of zidovudine and lamivudine in neonates following coadministration of oral doses every 12 hours.

Moodley D, Pillay K, Naidoo K, Moodley J, Johnson MA, Moore KH, Mudd PN Jr, Pakes GE.

J Clin Pharmacol. 2001 Jul;41(7):732-41.

PMID:
11452705
20.

Randomized, double-blind comparison of two nelfinavir doses plus nucleosides in HIV-infected patients (Agouron study 511).

Saag MS, Tebas P, Sension M, Conant M, Myers R, Chapman SK, Anderson R, Clendeninn N; Virqacept Collaborative Study Group.

AIDS. 2001 Oct 19;15(15):1971-8.

PMID:
11600825

Supplemental Content

Support Center